Anti-VEGF for the Management of Diabetic Macular Edema
Diabetic retinopathy (DR) is an important cause of vision loss around the world, being the leading cause in the population between 20 and 60 years old. Among patients with DR, diabetic macular edema (DME) is the most frequent cause of vision impairment and represents a significant public health issu...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2014/632307 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849695287798398976 |
|---|---|
| author | Francisco Rosa Stefanini Emmerson Badaró Paulo Falabella Michael Koss Michel Eid Farah Maurício Maia |
| author_facet | Francisco Rosa Stefanini Emmerson Badaró Paulo Falabella Michael Koss Michel Eid Farah Maurício Maia |
| author_sort | Francisco Rosa Stefanini |
| collection | DOAJ |
| description | Diabetic retinopathy (DR) is an important cause of vision loss around the world, being the leading cause in the population between 20 and 60 years old. Among patients with DR, diabetic macular edema (DME) is the most frequent cause of vision impairment and represents a significant public health issue. Macular photocoagulation has been the standard treatment for this condition reducing the risk of moderate visual loss by approximately 50%. The role of vascular endothelial growth factor (VEGF) in DR and DME pathogenesis has been demonstrated in recent studies. This review addresses and summarizes data from the clinical trials that investigated anti-VEGF for the management of DME and evaluates their impact on clinical practice. The literature searches were conducted between August and October 2013 in PubMed and Cochrane Library with no date restrictions and went through the most relevant studies on pegaptanib, ranibizumab, bevacizumab, and aflibercept for the management of DME. The efficacy and safety of intravitreal anti-VEGF as therapy for DME have recently been proved by various clinical trials providing significantly positive visual and anatomical results. Regarding clinical practice, those outcomes have placed intravitreal injection of anti-VEGF as an option that must be considered for the treatment of DME. |
| format | Article |
| id | doaj-art-d6cc1404c6fb4d57ae1d2a9d14cdc3ec |
| institution | DOAJ |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-d6cc1404c6fb4d57ae1d2a9d14cdc3ec2025-08-20T03:19:49ZengWileyJournal of Immunology Research2314-88612314-71562014-01-01201410.1155/2014/632307632307Anti-VEGF for the Management of Diabetic Macular EdemaFrancisco Rosa Stefanini0Emmerson Badaró1Paulo Falabella2Michael Koss3Michel Eid Farah4Maurício Maia5Retina Division, Retina Division, Department of Ophthalmology and Visual Sciences, Federal University of São Paulo (UNIFESP), 821 Botucatu Street, 2nd Floor, 04023-062 São Paulo, SP, BrazilRetina Division, Retina Division, Department of Ophthalmology and Visual Sciences, Federal University of São Paulo (UNIFESP), 821 Botucatu Street, 2nd Floor, 04023-062 São Paulo, SP, BrazilRetina Division, Retina Division, Department of Ophthalmology and Visual Sciences, Federal University of São Paulo (UNIFESP), 821 Botucatu Street, 2nd Floor, 04023-062 São Paulo, SP, BrazilDoheny Eye Institute, Department of Ophthalmology, Keck School of Medicine, University of Southern California, 1450 San Pablo Street, Los Angeles, CA 900033, USARetina Division, Retina Division, Department of Ophthalmology and Visual Sciences, Federal University of São Paulo (UNIFESP), 821 Botucatu Street, 2nd Floor, 04023-062 São Paulo, SP, BrazilRetina Division, Retina Division, Department of Ophthalmology and Visual Sciences, Federal University of São Paulo (UNIFESP), 821 Botucatu Street, 2nd Floor, 04023-062 São Paulo, SP, BrazilDiabetic retinopathy (DR) is an important cause of vision loss around the world, being the leading cause in the population between 20 and 60 years old. Among patients with DR, diabetic macular edema (DME) is the most frequent cause of vision impairment and represents a significant public health issue. Macular photocoagulation has been the standard treatment for this condition reducing the risk of moderate visual loss by approximately 50%. The role of vascular endothelial growth factor (VEGF) in DR and DME pathogenesis has been demonstrated in recent studies. This review addresses and summarizes data from the clinical trials that investigated anti-VEGF for the management of DME and evaluates their impact on clinical practice. The literature searches were conducted between August and October 2013 in PubMed and Cochrane Library with no date restrictions and went through the most relevant studies on pegaptanib, ranibizumab, bevacizumab, and aflibercept for the management of DME. The efficacy and safety of intravitreal anti-VEGF as therapy for DME have recently been proved by various clinical trials providing significantly positive visual and anatomical results. Regarding clinical practice, those outcomes have placed intravitreal injection of anti-VEGF as an option that must be considered for the treatment of DME.http://dx.doi.org/10.1155/2014/632307 |
| spellingShingle | Francisco Rosa Stefanini Emmerson Badaró Paulo Falabella Michael Koss Michel Eid Farah Maurício Maia Anti-VEGF for the Management of Diabetic Macular Edema Journal of Immunology Research |
| title | Anti-VEGF for the Management of Diabetic Macular Edema |
| title_full | Anti-VEGF for the Management of Diabetic Macular Edema |
| title_fullStr | Anti-VEGF for the Management of Diabetic Macular Edema |
| title_full_unstemmed | Anti-VEGF for the Management of Diabetic Macular Edema |
| title_short | Anti-VEGF for the Management of Diabetic Macular Edema |
| title_sort | anti vegf for the management of diabetic macular edema |
| url | http://dx.doi.org/10.1155/2014/632307 |
| work_keys_str_mv | AT franciscorosastefanini antivegfforthemanagementofdiabeticmacularedema AT emmersonbadaro antivegfforthemanagementofdiabeticmacularedema AT paulofalabella antivegfforthemanagementofdiabeticmacularedema AT michaelkoss antivegfforthemanagementofdiabeticmacularedema AT micheleidfarah antivegfforthemanagementofdiabeticmacularedema AT mauriciomaia antivegfforthemanagementofdiabeticmacularedema |